Overview

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in

Status:
Completed

Trial end date:
2019-11-29

Target enrollment:

Participant gender:

Summary

This is a Phase 1, open-label, two-part, safety, PK, and activity study designed to characterize the DDI potential of tazemetostat. Tazemetostat will be taken orally BID continuously in 28-day cycles in both study parts.

Phase:

Phase 1

Details

Lead Sponsor:

Epizyme, Inc.

Treatments:

Cytochrome P-450 CYP3A Inhibitors
Fluconazole
Omeprazole
Repaglinide